Russo Giorgio I, Cimino Sebastiano, Giranio Giorgia, Regis Federica, Favilla Vincenzo, Privitera Salvatore, Motta Fabio, Caltabiano Rosario, Stenzl Arnulf, Todenhöfer Tilman, Morgia Giuseppe
Urology section, Department of Surgery, University of Catania, Catania, Italy.
Urology section, Department of Surgery, University of Catania, Catania, Italy.
Urol Oncol. 2018 May;36(5):240.e21-240.e26. doi: 10.1016/j.urolonc.2018.01.012. Epub 2018 Feb 9.
To evaluate the association between metabolic syndrome (MetS) and proliferative inflammatory atrophy (PIA) in patients with suspected prostate cancer (PCa).
From June 2015 to July 2016, we conducted the FIERY (Flogosis Increased Events of pRostatic biopsY) study at the Urology section, Department of Surgery of the University of Catania (Local registration number: #131/2015). A total of 205 patients with elevated prostate-specific antigen (≥ 4 ng/ml) or clinical suspicion of PCa who underwent primary transperineal prostate biopsy were included in this cross-sectional study. The assessment of PIA, HGPIN, and PCa were performed by 2 experienced pathologists and samples were investigated for the presence of an inflammatory infiltrate, according to the Irani score. Primary and secondary Gleason grade of tumor in positive biopsies were evaluated according to the 2016 ISUP Modified Gleason System.
In the entire cohort, median age was 68.0 (interquartile range: 62.0-74.5), median prostate-specific antigen was 6.5 (interquartile range: 5.51-9.57). The prevalence of MetS was 34.1%, the detection rate of PCa was 32.7%, the rate of PIA was 28.3%, the rate of HGPIN was 32.2%, whereas the rate of severe intraprostatic inflammation (Irani-score ≥4) was 28.8%. When comparing clinical and histological variables in patients without and with PIA, metabolic aberrations where not significantly different in both groups. We did not find statistical association in detection rate of PCa (29.3% vs. 34.0%; P = 0.07) and HGPIN (27.6% vs. 34.0%; P = 0.37) in patients with and without PIA, respectively. When considering metabolic aberrations, MetS was not associated with Irani-score ≥4 (28.6% vs. 28.4%; P = 0.96) and none of each component was statistically predictive of severe inflammation. At the multivariable logistic regression analysis, PIA, HGPIN, and MetS were not associated with greater risk of PCa.
In this study, we did not show an association between MetS and PIA and PCa. Although the small sample size and the cross-sectional nature of the study, we do not suppose that MetS could be associated with greater evidence of PIA. Further studies should be conducted to evaluate the exact nature of this pathological lesion.
评估疑似前列腺癌(PCa)患者中代谢综合征(MetS)与增殖性炎性萎缩(PIA)之间的关联。
2015年6月至2016年7月,我们在卡塔尼亚大学外科泌尿外科进行了FIERY(前列腺活检中炎症增加事件)研究(当地注册号:#131/2015)。本横断面研究纳入了205例前列腺特异性抗原升高(≥4 ng/ml)或临床怀疑患有PCa且接受了经会阴前列腺穿刺活检的患者。PIA、高级别前列腺上皮内瘤变(HGPIN)和PCa的评估由2名经验丰富的病理学家进行,并根据Irani评分对样本进行炎症浸润检查。根据2016年国际泌尿病理学会(ISUP)改良Gleason系统评估阳性活检中肿瘤的主要和次要Gleason分级。
在整个队列中,中位年龄为68.0岁(四分位间距:62.0 - 74.5);中位前列腺特异性抗原为6.5(四分位间距:5.51 - 9.57)。MetS的患病率为34.1%,PCa的检出率为32.7%,PIA的发生率为28.3%,HGPIN的发生率为32.2%;而前列腺内严重炎症(Irani评分≥4)的发生率为28.8%。比较有无PIA患者的临床和组织学变量时,两组的代谢异常无显著差异。在有和无PIA的患者中,PCa的检出率(29.3%对34.0%;P = 0.07)和HGPIN(27.6%对34.0%;P = 0.37)均未发现统计学关联。考虑代谢异常时,MetS与Irani评分≥4无关(28.6%对28.4%;P = 0.96),且各组成部分均无统计学意义上的严重炎症预测价值。在多变量逻辑回归分析中,PIA、HGPIN和MetS与PCa风险增加无关。
在本研究中,我们未显示MetS与PIA及PCa之间存在关联。尽管本研究样本量小且为横断面性质,但我们认为MetS不太可能与PIA的更多证据相关。应开展进一步研究以评估这种病理病变的确切性质。